Department of Oral Medicine, Hebrew University - Hadassah School of Dental Medicine, Jerusalem, Israel.
Oral Oncol. 2011 Feb;47(2):125-30. doi: 10.1016/j.oraloncology.2010.11.013. Epub 2010 Dec 16.
The objective of this study was to assess the efficacy of a novel visible-light therapy (VLT) device for the prevention of oral mucositis in hematopoietic stem cell transplantation (HSCT) patients. A VLT-device suitable for intra-oral use was applied to 20 patients undergoing HSCT. The study design was placebo-controlled, randomized and double-blind. Oral mucositis was assessed using the OMAS and WHO scales. Oral pain and acceptance levels were scored by the patient using a 10-step scale. Patients were evaluated once a week until day 21 post-HSCT. Mucositis rate, severity and pain score were compared. At the third visit, 1week post-HSCT, mucositis rates were significantly lower in the treatment group (for both WHO and OMAS p=0.02). Mucositis was also less severe in the treatment group (for WHO p=0.01; for OMAS p=0.01). Furthermore, the patients in the treatment group reported lower pain levels (p=0.04). The treatment was well tolerated and highly accepted, with no reports of adverse events related to the device. These findings suggest that the VLT-device is safe and effective for the prevention of oral mucositis in patients undergoing HSCT.
本研究旨在评估一种新型可见光疗法（VLT）设备预防造血干细胞移植（HSCT）患者口腔黏膜炎的疗效。将适用于口腔内使用的 VLT 设备应用于 20 例接受 HSCT 的患者。研究设计为安慰剂对照、随机和双盲。使用 OMAS 和 WHO 量表评估口腔黏膜炎。患者使用 10 分制评分表对口腔疼痛和接受程度进行评分。患者每周评估一次，直到 HSCT 后第 21 天。比较黏膜炎发生率、严重程度和疼痛评分。在第三次就诊时，即 HSCT 后 1 周，治疗组的黏膜炎发生率显著降低（WHO 和 OMAS 均为 p=0.02）。治疗组的黏膜炎也较轻（WHO 为 p=0.01；OMAS 为 p=0.01）。此外，治疗组患者报告的疼痛水平较低（p=0.04）。该治疗方法安全有效，患者接受度高，未报告与设备相关的不良事件。这些发现表明，VLT 设备对预防 HSCT 患者口腔黏膜炎是安全有效的。
